148 search results for: burden of disease
ADVENT at ERS-ISIAN 2025
Join experts Vibeke Backer, MD, DMSC, and Sietze Reitsma, MD, at an educational symposium involving a comprehensive exploration of the type 2 inflammation and its pivotal role in the pathogenesis and management of CRSwNP.
Pediatric Asthma Patient Case Tool: Ash
Review a patient case to learn more about identifying uncontrolled asthma and type 2 inflammation in pediatric patients
Type 2 Inflammation Contributes to Itch and Fibrois in PN
Join Dr. Kwatra outlining the micro itch cycle involving type 2 cell polarization and cytokines that directly affect fibroblasts to cause more immune dysregulation in PN.
Why Is It Important to Assess Lung Function in Pediatric Asthma?
Learn about FEV1pp and the downstream effects of lung function decline in children with severe asthma.
Factors Contributing to Diagnostic Delays in Bullous Pemphigoid
Dr. Donna Culton focuses on the challenges of diagnosis and the unmet needs for patients with BP
Broadening the Lens: Clinical and Immunological Insights That Inform CSU Management
Professors Metz, Netchiporouk, and Hawkes discuss the clinical features, pathophysiology, and therapeutic landscape of CSU, at EADV 2025.
ERS 2024 | Airway Remodeling: A Permanent or Transitory Consequence in Severe Asthma Patients?
Professors Celeste Porsbjerg and Klaus Rabe and Dr Mario Castro discuss the pathophysiology of airway remodeling and its impact on patients with severe asthma.
IFOS 2023 | Type 2 Inflammation and Clinically Relevant Improvements in CRSwNP
Dr. Stella Lee and Profs. Peter Hellings and Wytske Fokkens discuss type 2 inflammation, partnering with patients to improve outcomes, and real-world data on biologic effectiveness in CRSwNP.
ERS 2024 | Understanding Remission as a Treatment Goal in Pediatric Severe Asthma – Patient Case Introduction
In this ADVENT symposium at the 2024 European Respiratory Society conference, Dr. Leonard Bacharier describes a typical patient presentation in the pediatric asthma clinic and explores whether clinical remission is a goal of treatment for this patient and others like them.
Hindered Growth in Children Aged <12 Years with Moderate-to-Severe AD and Potential Improvement with Dupilumab Treatment
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr Amy Paller discusses how moderate-to-severe AD may hinder growth in pediatric patients and highlights data showing treatment with dupilumab may increase vertical growth in children of lower stature.
Broadening the Lens: Clinical and Immunological Insights That Inform CSU Management
Experience this engaging presentation by Professors Martin Metz, Elena Netchiporouk, and Jason Hawkes to explore emerging therapies for chronic spontaneous urticaria.
ERS 2024 | Panel Discussion: What Might Be Required for On-Therapy Remission in Pediatric Severe Asthma?
In this ADVENT symposium at the 2024 European Respiratory Society conference, Drs. Sharon Dell and Leonard Bacharier discuss the potential domains of on therapy clinical remission in pediatric severe asthma, emphasizing lung function as a key parameter for children.
